Cannabis Law Group's Medical Marijuana Legal Blog
The Historic Reclassification of Cannabis from Schedule I: What It Means for the U.S. Cannabis Industry in 2025
Cannabis was classified as a Schedule I substance since the CSA’s enactment in 1970, placing it alongside drugs like heroin and LSD, deemed to have no accepted medical use and high abuse potential. This designation created significant barriers for research, banking, and taxation for state-legal cannabis businesses. The push for reclassification gained momentum in October 2022, when President Biden directed the Department of Health and Human Services (HHS) and the Attorney General to review cannabis’s scheduling.
In August 2023, HHS recommended moving cannabis to Schedule III, citing its accepted medical use, moderate to low abuse potential, and lower risk of dependence compared to Schedule I and II drugs like heroin or oxycodone. The DEA proposed reclassification on May 21, 2024, initiating a 60-day public comment period that drew thousands of responses. Despite delays due to legal challenges and evidentiary hearings (held between January and March 2025), the DEA finalized the rule in January 2025, moving cannabis to Schedule III alongside drugs like ketamine, anabolic steroids, and Tylenol with codeine.
-
Has a currently accepted medical use in the U.S., supported by studies on conditions like chronic pain, nausea, and epilepsy.
-
Has a moderate to low potential for physical dependence and a high potential for psychological dependence, less severe than Schedule I or II drugs.
-
Remains a controlled substance, subject to DEA oversight, but with fewer restrictions than Schedule I.
However, this does not legalize recreational cannabis federally, nor does it fully align federal law with the 24 states, two territories, and D.C. that have legalized recreational use, or the 38 states with medical cannabis programs. State-licensed dispensaries must still navigate federal regulations, and cannabis products require U.S. Food and Drug Administration (FDA) approval for interstate commerce unless under an investigational new drug (IND) application.
-
Tax Relief for Cannabis Businesses:
-
Previously, Internal Revenue Code Section 280E prohibited cannabis businesses from deducting standard business expenses due to their Schedule I status, resulting in tax burdens as high as 70%.
-
As a Schedule III drug, businesses can now claim deductions for rent, payroll, and marketing, potentially saving millions annually.
-
This financial relief could fuel growth, enabling reinvestment in operations, hiring, and expansion.
-
-
Improved Banking Access:
-
Schedule I status deterred banks from serving cannabis businesses due to federal illegality, forcing many to operate cash-only.
-
Reclassification reduces risks for financial institutions, encouraging banks to offer loans, deposit accounts, and credit card processing.
-
While the SAFE Banking Act (still pending in 2025) would further protect banks, Schedule III status is a significant step toward financial inclusion.
-
-
Expanded Research Opportunities:
-
Schedule I restrictions limited cannabis research, requiring special DEA licenses and sourcing from a single approved facility.
-
Schedule III eases these barriers, allowing researchers to study cannabis from state-licensed dispensaries and conduct human trials without stringent oversight.
-
This could lead to FDA-approved cannabis-based medications and better data on benefits for conditions like anxiety, pain, and glaucoma.
-
-
Criminal Justice Implications:
-
Reclassification has a muted immediate impact on federal prosecutions, as simple possession cases are rare.
-
However, it supports President Biden’s 2022 pardons for low-level federal marijuana convictions and encourages state-level expungements.
-
Long-term, it may reduce disparities in arrests, which disproportionately affect communities of color.
-
-
Challenges and Unresolved Issues:
-
State-licensed dispensaries may need to register with the DEA as pharmacies to comply with Schedule III regulations, a process the DEA is ill-equipped to manage for 15,000+ dispensaries.
-
Cannabis remains subject to the Federal Food, Drug, and Cosmetic Act, requiring FDA approval for products, which could disrupt existing state markets.
-
Federal trademark protections and bankruptcy options remain unavailable, as cannabis is still illegal federally.
-
International treaty obligations, like the 1961 Single Convention on Narcotic Drugs, may complicate full descheduling.
-
While reclassification is a historic step, full federal legalization remains a work in progress. The Marijuana Opportunity Reinvestment and Expungement (MORE) Act, which would deschedule cannabis and address criminal justice reforms, and the SAFE Banking Act, protecting financial institutions, are under consideration in Congress but face hurdles in 2025. Public support for legalization is strong, with 68% of Americans favoring it in a 2023 Gallup poll, and 70% supporting reclassification per a 2023 Coalition for Cannabis Scheduling Reform survey. This momentum, coupled with global trends in countries like Canada and Uruguay, suggests further reforms are likely.
-
Licensing Consultation: We guide you through evolving federal and state licensing requirements, ensuring compliance with DEA and local rules.
-
Business Plan Development: Our team crafts compelling business plans that address new Schedule III regulations, financial projections, and community impact to strengthen your operations or license applications.
-
Incorporation Services: We handle business entity formation, incorporating your company to meet federal and state standards and protect your interests.
-
Tax and Banking Strategies: We help you leverage Section 280E relief and secure banking services, optimizing your financial operations.
-
Regulatory Compliance: We ensure adherence to CSA, FDA, and state laws, minimizing risks of penalties or license revocation.
-
Advocacy and Dispute Resolution: From regulatory appeals to trademark disputes, we provide robust representation to safeguard your business.